April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Prevalence of the Metabolic Syndrome in Diabetic Retinopathy
Author Affiliations & Notes
  • Lucas J. Wendel
    Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinic, Iowa City, Iowa
  • John J. Chen
    Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinic, Iowa City, Iowa
  • Emily S. Birkholz
    Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinic, Iowa City, Iowa
  • John G. Vallone
    Pathology, University of Southern California, Los Angeles, California
    Omics Laboratory, University of Iowa, Iowa City, Iowa
  • Michael D. Abramoff
    Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinic, Iowa City, Iowa
  • Vinit B. Mahajan
    Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinic, Iowa City, Iowa
    Omics Laboratory, University of Iowa, Iowa City, Iowa
  • Footnotes
    Commercial Relationships  Lucas J. Wendel, None; John J. Chen, None; Emily S. Birkholz, None; John G. Vallone, None; Michael D. Abramoff, None; Vinit B. Mahajan, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1264. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lucas J. Wendel, John J. Chen, Emily S. Birkholz, John G. Vallone, Michael D. Abramoff, Vinit B. Mahajan; Prevalence of the Metabolic Syndrome in Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1264.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the prevalence of metabolic syndrome in diabetic retinopathy.

Methods: : A retrospective chart review was completed of patients seen at the University of Iowa. 100 patients with proliferative diabetic retinopathy (PDR) requiring pars plana vitrectomy for either nonclearing vitreous hemorrhage or tractional retinal detachment between 2007 and 2010 were selected. Another 100 patients, with nonproliferative diabetic retinopathy (NPDR) during the same time period, were also randomly selected.The presence or absence of the metabolic syndrome (MS) was determined using the 2006 International Diabetes Foundation (IDF) definition. This definition requires central obesity, defined as a waist circumference >94cm for males and >80 cm for females be present. A BMI > 30 kg/m2 may be used as a surrogate for waist circumference. Two of the following criteria must also be met: serum triglycerides > 150mg/dl or specific treatment for this abnormality, serum HDL-cholesterol 85 mmHg or treatment for previously diagnosed hypertension. The final criteria is a fasting plasma glucose > 100 mg/dl or previously diagnosed type 2 diabetes.

Results: : The overall prevalence of metabolic syndrome was 66% (132 out of 200). There was no significant difference in the prevalence of MS between the PDR and NPDR groups, with rates of 64% and 61%, respectively. The average BMI was 33.6 + 7.7 kg/m2. 69.5% (139 our of 200) of the patients had a BMI >30 kg/m2. The NPDR cohort’s average BMI was 34.8 + 7.9 kg/m2, which was significantly higher than the average BMI of the PDR group, 32.4 + 6.65 kg/m2 (p<0.05). Overall, 92.5% of patients met the IDF criteria for hypertension, and 73.5% met the criteria for hyperlipidemia. There was no difference with regards to the hypertensive criteria, but NPDR patients were significantly more likely to meet criteria for hyperlipidemia (p<0.05).

Conclusions: : There is a high prevalence of the metabolic syndrome in patients with diabetic retinopathy. There was no difference in the prevalence of the metabolic syndrome between patients with severe proliferative retinopathy and those with less severe, nonproliferative retinopathy. It is interesting that the NPDR control group had higher BMI’s and were more likely to meet the criteria for hyperlipidemia.

Keywords: diabetes • clinical (human) or epidemiologic studies: risk factor assessment • metabolism 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×